Published Medical Literature

Study Identifies Potential Biomarker for Lung Squamous Cell Carcinoma

TROPION-Lung01: Dato-DXd vs Docetaxel in Advanced Lung Cancer

After PD-1 Inhibitors Fail: Is Ipilimumab an Option for Some With Metastatic Melanoma?

Adding IDO1 Inhibitor to Immunotherapy in PD-L1–High Metastatic NSCLC

Novel Tool May Predict Survival in Stage IV Melanoma After First-Line Immunotherapy

Advanced Melanoma: 10-Year Outcomes With Nivolumab and Ipilimumab Support Earlier Results

Neurologic Symptoms and Immunotherapy for Melanoma Brain Metastases: A View From New Zealand

Use of Cemiplimab in a 90-Year-Old Woman With Skin Cancer: Debunking Age ‘Myths’

Advanced Merkel Cell Carcinoma: Quality of Life With Immunotherapy

Immunotherapy for Melanoma: Can the Presence of Autoantibodies Predict Adverse Events?

Age, Sex, Genomic Profiles Matter: Choosing Immunotherapies for Younger Patients With NSCLC

LAG-3 and PD-1 Inhibition: Working Together to Activate Immune Responses in Melanoma

Hypoalbuminemia: An Independent Biomarker of Immunotherapy Response in Metastatic Melanoma?

Predicting Response to Immunotherapy in NSCLC: AI-Powered PD-L1 Tumor Proportion Score Analyzer

Triple-Negative Breast Cancer: Can Adding Atezolizumab to Chemotherapy Improve Survival?

Systemic Therapy for NSCLC: Prognostic Value of CT-Derived Body Composition Metrics

Oncolytic Virotherapy Plus Natural Killer T-Cell Immunotherapy Under Study in Breast Cancer

Who May Benefit From Telizotuzumab Vedotin in NSCLC? LUMINOSITY Trial Sheds Light

SC vs IV Immune Checkpoint Inhibition in NSCLC: Is One Better Than the Other?

Survival and Immune Checkpoint Inhibitor Efficacy in KRAS-Mutated NSCLC

Gastrointestinal Toxicity: Are All Antibody-Drug Conjugates Created Equal in Breast Cancer?

Can Circulating Biomarkers Predict Response to Immunotherapy in Metastatic Melanoma?

Use of Atezolizumab Plus Cabozantinib Under Study When Other Treatments Fail in NSCLC

Impact of Timely Comprehensive Genomic Profiling for Patients With Advanced NSCLC

KEYNOTE-716 Trial Update: Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma

Selecting First-Line Treatment in Metastatic NSCLC: Plasma Proteomes Take Center Stage

NSCLC and Malignant Pleural Effusion: Immune Checkpoint Inhibitor Plus Chemotherapy

Immunotherapy vs Chemoimmunotherapy: Which Is Best for Older Adults With NSCLC?

Newly Diagnosed Multiple Myeloma: Adding Elotuzumab to Standard Treatment

Outcomes With Immunotherapy for Metastatic NSCLC: An FDA Pooled Analysis

Neoadjuvant Cemiplimab-rwlc and Surgery for Skin Cancer Subtype: Follow-up Trial Data

Can Targeting the TACC3 Protein Improve Responses to T-DM1 in HER2-Positive Breast Cancer?

Locally Advanced NSCLC: Pembrolizumab Plus Risk-Adapted Radiotherapy Under Study

Phase III Trial Supports Use of Toripalimab Plus Chemotherapy in Stage III NSCLC

Immune Checkpoint Inhibitor Pneumonitis: Assessing Risk Factors in Patients With Lung Cancer

Checkpoint Inhibitor Plus Antibody-Drug Conjugate: A Good Pair in Metastatic Urothelial Cancer?

CANOPY-1: Adding Monoclonal Antibody to Immunotherapy Regimen in NSCLC

Selpercatinib vs Chemotherapy for RET Fusion–Positive NSCLC: Phase III Findings

Phase III Trial Supports Use of Amivantamab in NSCLC With EGFR Exon 20 Insertions

Neoadjuvant Chemoimmunotherapy for Locally Advanced NSCLC: Who May Benefit?

Chemoradiotherapy and Immune Checkpoint Inhibitors in NSCLC: Insights on Impact of Induction

Dual Immunotherapy in the First-Line Setting of NSCLC: Ready for Prime Time?

Maintenance Regimen After Autologous HCT in Relapsed Multiple Myeloma: Phase II Findings

Comparing Triplet Regimens in Newly Diagnosed Myeloma: Is There a Clear Winner?

More MagnetisMM-3 Results Support Elranatamab’s Potential in Myeloma

Biological Mechanisms Behind Immune Checkpoint Inhibitors in Bladder Cancer

Can a Novel Scoring System Predict Outcomes With CAR T-Cell Therapy for Myeloma?

Identifying Key Genes in Bladder Cancer May Improve Outcomes With Immunotherapy

Updated Phase III IKEMA Results Support Isatuximab-Based Regimen for Relapsed Myeloma

Update on New CAR T-Cell Therapy for Resistant Myeloma From Multicenter Study

Research Offers Insights on Resistance Mechanisms of BCMA CAR T-Cell Therapy for Myeloma

Prognostic Risk Score Model for Bladder Tumors Based on Immunotherapy-Related Long Noncoding RNAs

Strategies for Reversing Treatment Exhaustion in Immunologically Nonresponsive Urothelial Carcinoma

Bladder-Sparing Regimen Under Study in T1 High-Grade or T2 Bladder Cancer

Advanced Biliary Tract Cancer: Benefits Seen With Pembrolizumab Plus Chemotherapy in KEYNOTE-966

5-Year Follow-up From ZUMA-1: Axicabtagene Ciloleucel in Resistant LBCL

Using RNA-Sequencing Data to Establish a Prognostic Model for Bladder Cancer

Real-World Infection Picture With Bispecific Antibody Therapy for Multiple Myeloma

Lack of Success for Immunotherapy in Lung Cancer: Could the Reason Be Ineffective Priming of Cytotoxic T Lymphocytes?

Dual Targeted Therapy and Immunotherapy in Unresectable Resistant Liver Cancer

R-CHOP as Front-Line Therapy for Primary Mediastinal LBCL: A View From Jordan

Nivolumab Plus Ipilimumab: Tailored Immunotherapy Strategy for Metastatic Urothelial Cancer

Combination Therapy With Tyrosine Kinase and PD-1 Inhibitors in Unresectable Liver Cancer

BCMA/CD19-Targeting Immunotherapy for Newly Diagnosed Multiple Myeloma

How Lenvatinib Compares With Other Therapies for Nonviral, Unresectable Liver Cancer

Intravesical Drug-Delivery System Plus PD-1 Inhibitor Under Study in Urothelial Bladder Carcinoma

The Cost of CAR T-Cell Therapy in the Second-Line or Third-Line Setting in DLBCL

RNA Modification and Tumor Immunity in Lung Cancer: Predicting Outcomes With Neoadjuvant Immunotherapy

Combination Immunochemotherapy for Resistant Myeloma: Focus on Extramedullary Disease

Bispecific Antibody Glofitamab Under Study in Relapsed or Refractory DLBCL

Adjuvant Nivolumab for High-Risk Urothelial Cancer: Focus on Disease-Free Survival From CheckMate 274

Demographic Characteristics of Patients With Myeloma From the CARTITUDE Trial

Early Trial Results With Telisotuzumab Vedotin Plus Erlotinib in c-MET–Positive Lung Cancer

Cost Considerations of Beginning Treatment of CLL With Venetoclax Plus Obinutuzumab

COLUMBA Trial: Subcutaneous Versus Intravenous Daratumumab Therapy for Resistant Myeloma

Phase III Trial of Sacituzumab Govitecan in HR-Positive, HER2-Negative Advanced Breast Cancer

Phase III CASTOR Trial: Daratumumab-Based Regimen for Resistant Multiple Myeloma

5-Year Follow-up of KEYNOTE-042: Pembrolizumab Versus Chemotherapy in NSCLC

Neoadjuvant Chemotherapy and the Immune Landscape in Early-Stage Breast Cancer

Weighing the Cost-Effectiveness of Immunotherapy Combinations for Patients With DLBCL

PEARLS/KEYNOTE-091: Adjuvant Pembrolizumab in Completely Resected Stage IB–IIIA NSCLC

Pembrolizumab Plus Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355

Activity of Teclistamab in Resistant Myeloma Demonstrated in Early-Phase Study

Can Immunotherapy After Chemoradiotherapy Improve Outcomes in Clinical Stage III Lung Cancer?

MRD-Driven, Time-Limited Triplet Therapy Under Study in CLL

Can Biomarkers Predict Outcomes With Nivolumab in Refractory Biliary Tract Cancer?

Membrane-Bound IL-21–Expanded NK Cells Under Study in CLL

IMpassion050 Trial: Combining Standard of Care With Immunotherapy for High-Risk Breast Cancer

Phase III IKEMA Trial: Isatuximab, Carfilzomib, and Dexamethasone in Resistant Myeloma

Adding Durvalumab to Standard-of-Care Chemotherapy for Advanced Biliary Tract Cancer

Consider the Intestinal Environment in Predicting Immunotherapy Response in Liver Cancer

Overcoming Resistance to TP53-Mediated Chemoimmunotherapy in B-Cell Malignancies

Case Study of Larotrectinib in Mismatch Repair–Deficient TRK Fusion–Positive Colorectal Cancer

Use of Tisagenlecleucel at Outpatient Facilities for Patients With Lymphoma

Trial Update on Tiragolumab Plus Atezolizumab as First-Line Treatment of NSCLC

First-Line Radioimmunotherapy for Follicular Lymphoma: Long-Term Follow-up

CheckMate 816: Nivolumab Plus Chemotherapy for Resectable NSCLC

Using C-Reactive Protein Kinetics to Predict Immunotherapy Response in Metastatic Urothelial Carcinoma

Chemotherapy-Free GALEN Combination for Advanced Follicular Lymphoma

6-Year Trial Update on Ibrutinib Plus Rituximab Versus Chemoimmunotherapy for CLL

Treatment Duration of Venetoclax Plus Obinutuzumab in Patients With CLL

Diversity in Macrophage Function Among LC3-Associated Phagocytosis of AML Bone Marrow

First-Line Ibrutinib Plus Rituximab in Elderly Patients With Mantle Cell Lymphoma

Combination of Obinutuzumab, Ibrutinib, and Venetoclax for Untreated High-Risk CLL

Loncastuximab Tesirine-lpyl for DLBCL: Quality of Life for Older Versus Younger Patients

CheckMate 9ER: Patient-Reported Outcomes With Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma

Immunogenicity Profile of Tisagenlecleucel in Diffuse Large B-Cell Lymphoma

Phase Ib/II Clinical Trial: Does Regimen Treatment for CLL Reduce Infusion-Related Reactions?

Can Radiomic Signatures Predict Response to Nivolumab in Advanced Kidney Cancer?

Clear Cell Renal Cell Carcinoma: Characterization of Immune Cell Infiltration and Lymphocyte Heterogeneity

The Impact of Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer

Daratumumab Plus Carfilzomib and Dexamethasone in Resistant Myeloma: CANDOR Trial Update

Use of Cabozantinib Plus Nivolumab After Immunotherapy in Metastatic Urothelial Carcinoma

Adjuvant Atezolizumab Versus Best Supportive Care in Resected Early-Stage NSCLC: IMpower010 Results

Polatuzumab Vedotin-piiq–Based Salvage Chemotherapy for DLBCL

Zanubrutinib-Based Therapy for CLL: Focus on MRD-Driven Treatment Duration

Research Update on Bispecific CAR T-Cell Therapy for Resistant Multiple Myeloma

Does Immunotherapy Increase the Risk of Thromboembolic Events in Patients With Metastatic Kidney Cancer?

Early-Phase Study of Cabozantinib Plus Atezolizumab in Advanced Triple-Negative Breast Cancer

Neutrophil-to-Eosinophil Ratio: Predictive Measure of Therapeutic Outcomes in Kidney Cancer?

Polatuzumab Vedotin-piiq–Based Therapy for Previously Untreated DLBCL: POLARIX Trial

Older Patients With Mantle Cell Lymphoma: Phase II Trial Focuses on Ibrutinib Plus Rituximab

Tisagenlecleucel Versus Standard of Care in Second-Line Therapy for Aggressive B-Cell Lymphomas

Axicabtagene Ciloleucel Versus Standard-of-Care Therapy for Resistant B-Cell Lymphoma

Intratumoral Immune Therapy for Recurrent Breast Cancer

Complementary Strategies to Manage CLL: Focus on Restoring Immune Function

Combination Immunotherapy for Patients With Metastatic Kidney Cancer Undergoing Hemodialysis: Case Reports

Use of Toripalimab in the Second-Line Setting for Advanced Urothelial Carcinoma

Richter Transformation in CLL: From Pathophysiology to Treatment

Novel PET Assessment of Response to Daratumumab Quadruplet in Multiple Myeloma

Is Neoadjuvant PD-1 Inhibition Plus Chemotherapy of Benefit in Locally Advanced NSCLC?

Can Novel Anti-HGF Antibody Plus Chemotherapy Inhibit MET Signaling in Refractory AML?

Tremelimumab Plus Cryoablation in Metastatic Renal Cell Carcinoma: A Pilot Study

Real-World View From Germany: Bevacizumab-Containing Therapy for Locally or Metastatic Breast Cancer

Sintilimab Plus Pemetrexed and Platinum for NSCLC: Updated ORIENT-11 Study Results

Combining BTK and BCL2 Inhibitors in Front-Line Treatment of CLL: Phase II Trial

KEYNOTE-010 Update: Long-Term Benefits Continue With Pembrolizumab in NSCLC

Patterns of Infectious Complications in Patients With Myeloma After BCMA CAR T-Cell Therapy

Treatment of Bladder Cancer After Platinum and PD-1/L1 Inhibitor Therapy: Real-World Outcomes

Lenalidomide Maintenance Therapy for Multiple Myeloma: Is Longer Better?

Kidney Cancer Case Report: Rechallenge With Nivolumab After Immune-Related Adverse Events

Is T-DXd Active Against HER2-Mutant NSCLC?

Triplet Regimen Under Study in Frail Patients Newly Diagnosed With Multiple Myeloma

Can Axitinib Amid Immunotherapy Sequences Improve Outcomes in Renal Cell Carcinoma?

Early-Phase Study of KITE-585 in Resistant Multiple Myeloma

Case Report: Older Woman With Metastatic Bladder Cancer Responds to Pembrolizumab

ERBB2-Positive Breast Cancer: How Does T-DM1 Measure Up Against Standard Neoadjuvant Treatment?

Stem Cell–Derived Dendritic Cells With Radiotherapy Under Study in Preclinical Breast Cancer Models

Is Isatuximab Plus Carfilzomib/Dexamethasone the New Standard of Care in Relapsed Multiple Myeloma?

CheckMate 274: Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma

Cohort 2 of KEYNOTE-023: Pembrolizumab-Based Combination for Resistant Myeloma

Avelumab in Electrochemotherapy-Resistant Merkel Cell Carcinoma: Case Report

RATIONALE 304: Tislelizumab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

Adjuvant Treatment of Early-Stage Breast Cancer: T-DM1 Versus Paclitaxel Plus Trastuzumab

CLL14 Trial: Impact of Venetoclax Plus Obinutuzumab Treatment on Health-Related Quality of Life

Enfortumab Vedotin-ejfv Under Study in Cisplatin-Ineligible Urothelial Carcinoma

Isatuximab Under Study in Daratumumab-Refractory Multiple Myeloma

Rare Case of Bladder Metastasis of Kidney Cancer: Potential Role of Genomic Analysis

Effective Combination Therapy for COVID-19 Featured in a Patient With Lung Cancer

Proof-of-Concept Trial of Chemotherapy Plus Immune Checkpoint Inhibitor in Unresectable NSCLC

Feasibility Study in Upper Tract Urothelial Cancer: Neoadjuvant Pembrolizumab Before Surgery

Can Combination of Targeted Therapy and Immunotherapy Improve Surgical Outcomes in Renal Cell Carcinoma?

Adding Stereotactic Body Radiotherapy to Immunotherapy for Early-Stage NSCLC

Does Ibrutinib Pretreatment Reduce the Risk of Obinutuzumab-Related Infusion Reactions in CLL?

Larotrectinib for Advanced Lung Cancer With Novel NCOR2-NTRK1 Fusion: Case Study

CARTITUDE-1 Trial: Targeting BCMA With CAR T-Cell Therapy for Myeloma

Combination Therapy for Metastatic Urothelial Bladder Carcinoma With FGFR3 Mutation: A Case Study

Metastatic Kidney Cancer: Targeted Therapy Plus Immune Checkpoint Inhibition

Interim Analysis of Phase III Trial of Combination Therapies for Resistant Myeloma

Medicare-Insured Patients With Advanced Lung Cancer: Does First-Line Immunotherapy Improve Survival?

Identifying Bladder Cancer Subtypes by Metabolic Characteristics: Therapeutic Implications

Standard Versus Escalated Dose of Ofatumumab in Chemoimmunotherapy Regimen for CLL

Adjuvant Nivolumab for Patients With High-Risk Muscle-Invasive Urothelial Carcinoma

Locally Advanced Basal Cell Carcinoma: Use of Cemiplimab-rwlc After Hedgehog Inhibitor Therapy

Camrelizumab Treatment in Upper Tract Urothelial Carcinoma: Case Report

ORIENT-12 Trial: Sintilimab Plus Standard Chemotherapy for Metastatic Lung Cancer

Do Trial Findings Translate to Real-World Treatment Success in Metastatic Kidney Cancer?

Mixed Results With Rucaparib in ATLAS Trial in Metastatic Urothelial Cancer

CALGB 90601: Combination Gemcitabine and Cisplatin With Bevacizumab in Urothelial Carcinoma

Resistant Urothelial Carcinoma: Organ-Specific Response to Pembrolizumab

Nivolumab for Sarcomatoid Renal Cell Carcinoma With Metastases: Case Report

Neoadjuvant Combination Immunotherapy for Operable Lung Cancer: NEOSTAR Trial Update

Breast Tumor Microenvironment: Differences in Black Women?

Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report

Case of Therapy-Related AML and Myeloma: Decitabine/Venetoclax and Daratumumab

Do Men and Women With Urinary Bladder Cancer Respond Differently to BCG Immunotherapy?

TRAXAR Trial: Adding Novel Monoclonal Antibody to Axitinib in Advanced Kidney Cancer

Eomesodermin: A Master Regulator of CD8-Positive T Cells in CLL?

KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer

Immune Checkpoint Inhibitors and Kidney Cancer: Immune-Related Adverse Events and Outcomes

TP53-Mutated Bladder Cancer: Identifying Patients Who May Benefit From Immunotherapy

First-Line Pembrolizumab Monotherapy in Advanced Non–Clear Cell Renal Cell Carcinoma

Case Study: Immunomodulatory Mechanism and Antimyeloma Effect of Daratumumab

IMWG Offers Updated Recommendations for Managing Myeloma-Related Bone Disease

Do Sex-Specific Hormones Influence Outcomes With Immunotherapy for Kidney Cancer?

Can Osimertinib Plus Bevacizumab Improve Outcomes in Advanced EGFR T790M–Mutated Lung Cancer?

Daratumumab-Based Regimens and Minimal Residual Disease in Patients With Myeloma

CheckMate 9LA: First-Line Immunotherapy Plus Chemotherapy in NSCLC

Daratumumab-Based Therapy for Newly Diagnosed Myeloma: Patient-Reported Outcomes From MAIA Trial

Smoking Behavior in Patients With Early-Stage NSCLC Enrolled in Clinical Trial

Immunotherapy for Urothelial Cancer: Balancing Benefits and Risks

Ibrutinib-Refractory CLL: Focus on B Leukemic Cells

Preferred Treatment for Invasive Bladder Cancer: Intravesical Immunotherapy or Radical Cystectomy?

Neoadjuvant Chemoimmunotherapy for Resectable Stage IIIA NSCLC

Gemogenovatucel-T Immunotherapy for Ovarian Cancer Maintenance

Adding ErbB Inhibitor to Standard Chemotherapy for HER2-Positive Breast Cancer

Toxicity Associated With Concomitant Ruxolitinib and Avelumab in Merkel Cell Carcinoma

Intravesical Nadofaragene Firadenovec in Non–Muscle Invasive Bladder Cancer

Ramucirumab Plus Docetaxel in Urothelial Carcinoma: Patient-Reported Outcomes From RANGE Trial

Combining Novel Monoclonal Antibody With Radiotherapy for NSCLC

Merkel Cell Carcinoma and Interstitial Lung Disease: Case Report on Use of Pembrolizumab

Is Immunotherapy Safe for Patients With Myeloma and HBV Infection?

Extended Follow-up From KEYNOTE-426: Pembrolizumab Plus Axitinib in Kidney Cancer

Pembrolizumab Plus T-Cell Inducer Under Study in Triple-Negative Breast Cancer

Atezolizumab Plus VEGF Inhibition in Stage IV Lung Cancer

Can Ibrutinib Enhance CAR T-Cell Production for Patients With CLL?

Combining Tivozanib and Nivolumab in Advanced Renal Cell Carcinoma

Is Immunotherapy Combination Effective as Salvage Treatment in Metastatic Renal Cell Carcinoma?

Long-Term Treatment Strategy for Myeloma: Optimal Selections Based on Stage

Novel PD-1 Antibody Shows Activity in Advanced Lung Cancer

Presence of Immune Checkpoint Markers Identified in Cutaneous Angiosarcoma

Immune Checkpoint Inhibition Among Patients With Dermatologic and Hematologic Cancers

Trastuzumab Monotherapy for Older Patients With HER2-Positive Breast Cancer

Case Study: Neoadjuvant Pembrolizumab in Chemoresistant Urothelial Carcinoma

Study Explores Adoptive Cell Therapy for Refractory NSCLC

Venetoclax Plus Rituximab in Relapsed CLL: Genomic Complexity and Outcomes

Targeting Bladder Carcinoma in Situ With Novel Gene Therapy

Multisite Progression of Merkel Cell Carcinoma and Simultaneous Immune-Related Adverse Events

DANUBE Trial: Survival Outcomes With Durvalumab in Advanced Urothelial Carcinoma

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Combination Immunochemotherapy in Locally Advanced or Metastatic NSCLC

Therapeutic Update in AML: Genomic Assessment Is Key

COVID-19 and Multiple Myeloma: Update From Stockholm

Study Explores Potential Prognostic Indicators for Papillary Thyroid Carcinoma

Triple-Negative Breast Cancer: Mixed 19-Peptide Vaccine Monotherapy

Integrin Inhibitor Under Study as Targeted Therapy for Ovarian Cancer

Potential Biomarker Investigated for Merkel Cell Carcinoma

Selecting Initial Therapy in NSCLC: First Step Is Histology

How Comorbidities May Affect Response to Idelalisib-Based Therapy in CLL

Fixed-Duration Combination Regimen Under Study in CLL

Response to Neoadjuvant Immunotherapy for Rectal Cancer: Case Series

Can Immunoglobulin Expression Predict Survival in Patients With AML?

Durvalumab in Advanced Lung Cancer: Final Overall Survival Data From ATLANTIC Trial

Case of Tumor-Lysis Syndrome After Combination CLL Therapy

Phase II Trial Focuses on Isatuximab for Resistant Myeloma

Long-Term Outcomes With Pembrolizumab for NSCLC and Brain Metastases

Real-World Data From Czech Study Group on CD20 Antibody Plus Chemotherapy for CLL

Quality of Life During Pembrolizumab Treatment for Metastatic Triple-Negative Breast Cancer

Subcutaneous Versus Intravenous Pertuzumab/Trastuzumab in Early Breast Cancer: Patient Perspective

Novel Chimeric Monoclonal Antibody Under Study in Metastatic Colorectal Cancer

Novel Antibody-Drug Conjugate Under Study in Platinum-Sensitive Ovarian Cancer

Phase III Trial of Triplet Regimen for HER2-Positive Metastatic Breast Cancer

First-line Osimertinib and Bevacizumab Treatment in Metastatic EGFR-Mutant Lung Cancer

Combination Therapy of Vaccine and Durvalumab in Advanced Ovarian Cancer

Combination of Abemaciclib, Pembrolizumab, and Anastrozole in Metastatic Breast Cancer

Update on Role of Subcutaneous Daratumumab in Multiple Myeloma

Pneumonitis in Patients Treated With Chemotherapy or Immunotherapy

Response of Early-Stage Colon Cancer to Neoadjuvant Immunotherapy

Safety of Combination Triplet for Lung Cancer in KEYNOTE-189

Pomalidomide-Based Therapy for Multiple Myeloma: Results From MM-014 Trial

Tumor-Infiltrating Lymphocytes in Metastatic Lung Cancer

Is Proteome Instability a Treatment Opportunity in Mismatch Repair–Deficient Colorectal Cancers?

Measles Virus Vaccine Under Study in Multiple Myeloma

Upfront FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: TRIBE2 Trial Update

Head-to-Head Trial Compares Bevacizumab/Platinum-Based Regimens in Recurrent Ovarian Cancer

Rare Case of Dual Multiple Myeloma and AML: Combination Therapy Active for Both

Nivolumab Prior to Surgery in Patients With Merkel Cell Carcinoma

Biomarkers May Predict Sensitivity to Combined PARP and PD-1 Inhibition in Ovarian Cancer

CENTAURUS Trial: Daratumumab Monotherapy for Smoldering Multiple Myeloma

Chemoimmunotherapy vs Chemotherapy in CLL: 5-Year Follow-up of Complement 1 Trial

New Role Explored for Lenalidomide: With Chemotherapy for Older Patients With AML

Durvalumab in Unresectable NSCLC: Are Outcomes Affected by PD-L1 Expression?

Subcutaneous Versus Intravenous Daratumumab in Resistant Multiple Myeloma

Rocapuldencel-T Plus Sunitinib in Metastatic Renal Cell Carcinoma

CAR T-Cell Strategy for Myeloma: Two Targets, Fewer Relapses

Pembrolizumab With Bevacizumab in Metastatic Kidney Cancer

Pembrolizumab Plus Chemotherapy for Metastatic Lung Cancer: Quality-of-Life Outcomes

Use of Duvelisib After Ofatumumab in Resistant CLL/SLL

Phase I Trial of Immunotherapy Plus Radiotherapy for Advanced Melanoma

Treatment Potential of CAR-Transduced Natural Killer Cells in CLL

Pathologic Complete Response With Pembrolizumab for Triple-Negative Breast Cancer

Circulating Tumor DNA Assays and Response to Melanoma Treatment

Meta-analysis Supports Maintenance Therapy for Reducing CLL Progression

Daratumumab-Based Combination Therapy in Newly Diagnosed Myeloma: GRIFFIN Study Update

Adding Pemetrexed to Bevacizumab in Advanced Nonsquamous Lung Cancer

GVAX Vaccine With Cyclophosphamide and Pembrolizumab in Advanced Colorectal Cancer

CLL-Stereotyped Immunoglobulin Gene Rearrangements in Normal B-Cell Subsets

Sequential Combination Therapy for Chronic Lymphocytic Leukemia

Tumor Mutation Burden in Metastatic NSCLC: Predictive of Response to Pembrolizumab?

Predicting Relapse of Stage III Melanoma Using Circulating Tumor Cells

Moxetumomab Pasudotox Therapy Under Study in Resistant Hairy Cell Leukemia

Early Research Findings on CAR T-Cell Therapy in Resistant Multiple Myeloma

Does Immunotherapy Offer Survival Advantage in Resected Cutaneous Melanoma?

Early-Phase Study of Acalabrutinib Plus Obinutuzumab in CLL

AMG 420 T-Cell Therapy Induces Responses in Resistant Multiple Myeloma

Potential Effect of Antigen Drive on T-Cell Repertoire in CLL

Second-Line Gemcitabine With Dual Antibody Therapy for ERBB2-Positive Metastatic Breast Cancer

Targeting B-Cell Maturation Antigen in Resistant Multiple Myeloma

Does Adding Cetuximab to Radiotherapy Improve Survival in Unresectable Lung Cancer?

Locally Advanced Nasopharyngeal Cancer: Induction Therapy With Nimotuzumab Plus Chemotherapy

Use of Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma

Immune-Related Adverse Events and Recurrence-Free Survival in Melanoma

Responses to Novel Drug Combination Among Patients With Multiple Myeloma

Quality of Life of Melanoma Survivors Treated With Pembrolizumab

Monoclonal Antibody Combination Under Study in Rare Metastatic Kidney Cancer

Is Combined Checkpoint Blockade Effective in Treating Uveal Melanoma?

Everolimus Plus Bevacizumab in Recurrent Ovarian Cancer

Combination of Rituximab and High-Dose Methylprednisolone for High-Risk Patients With CLL

BCMA-Targeted Immunoconjugate for Resistant Multiple Myeloma

Role of Bevacizumab in Patients With Advanced NSCLC With Liver Metastases

Adding Bevacizumab to Platinum-Based Chemotherapy in Head/Neck Squamous Cell Carcinoma

Does Pathologic Response to Immunotherapy Differ in Australian and European Patients With Melanoma?

Cell Death Pathways in Targeted Therapy for Renal Cell Carcinoma

Shedding Light on Elotuzumab’s Mechanism of Action in Treating Myeloma

Can Immunotherapy Improve Response to Salvage Chemotherapy in Head/Neck Cancer?

Case Studies Focus on Possible Link Between Nivolumab and Pericardial Effusion

Personalized Algorithm to Predict Response to Immunotherapy for Melanoma

FOLFOXIRI Plus Panitumumab in First-Line Treatment of Colorectal Cancer

Can Gut Microbiota Influence Response to Immunotherapy in Patients With Melanoma?

Chemoradiotherapy Plus Avelumab in Advanced Head/Neck Cancer

IMMUNED Trial: Neoadjuvant Immunotherapy for Stage IV Melanoma With No Evidence of Disease

First-in-Class Pegilodecakin Plus Immunotherapy Under Study in Lung Cancer

BEACON CRC Trial: Improved Outcomes With Triplet Therapy in Colorectal Cancer

Olaparib Plus Durvalumab Treatment of BRCA-Mutant Ovarian Cancer: MEDIOLA Trial

JAVELIN Solid Tumor Trial: Avelumab Monotherapy for Metastatic Kidney Cancer

Adjuvant Trastuzumab and Cardiac Toxicities in Patients With Breast Cancer

KATE2 Trial: Updated Overall Survival With Immunotherapy Combination in Advanced Breast Cancer

Bevacizumab Plus Erlotinib or Erlotinib Alone in EGFR-Mutated Lung Cancer

Efficacy of Nivolumab in Patients With Advanced Ocular or Mucosal Melanoma

Nivolumab Plus Ipilimumab in Advanced Kidney Cancer: CheckMate 214 Update

Long-Term Outcomes With Nivolumab Plus Ipilimumab for Melanoma Brain Metastases

Does the Mode of Disease Progression Affect Outcomes in CLL?

Long-Term Phase III Trial Results With Adjuvant Ipilimumab for Advanced Melanoma

Cancer-Testis Antigens: Immunotherapy Targets for Merkel Cell Carcinoma?

Long-Term Survival With Nivolumab in Advanced Lung Cancer

Why Do Some Patients With Melanoma Fail to Respond to Immunotherapy?

Pembrolizumab for Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma: A Case Study

Final Results of MARIANNE Trial of T-DM1 in HER2-Positive Advanced Breast Cancer

Phase III Trial Shows Venetoclax/Obinutuzumab Active in First-Line Treatment of CLL

New Outcome Measure Posited for Immunotherapy in Advanced Melanoma

Early Results With Cirmtuzumab/Ibrutinib Therapy for CLL

Targeting Leukemic Stem Cells in CML With Immunotherapy

Immunotherapy Under Study in Resistant CLL: ZUMA-8 Trial

Daratumumab and Lenalidomide/Dexamethasone in Multiple Myeloma MAIA Trial

Pamiparib Plus Tislelizumab Being Studied Further in Ovarian Cancer

Nivolumab for Advanced Melanoma: 5-Year Survival

Two Phase III Trials Evaluating Daratumumab-Based Therapies for Multiple Myeloma

Case Study of ‘Long-Lasting’ Response to Nivolumab in Patient With BRCA1 Mutation

Is Pembrolizumab of Benefit in Oligometastatic Lung Cancer After Local Ablative Therapy?

Dosing Schedule for Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma

Niraparib Plus Pembrolizumab in Recurrent Platinum-Resistant Ovarian Carcinoma

Nivolumab for Advanced Lung Cancer: 5-Year Survival

Bevacizumab for Ovarian Cancer: Final Overall Survival Analysis of GOG-0218

Adjuvant Trastuzumab for HER2-Positive Breast Cancer: Results of Two Phase III Trials

Pembrolizumab Therapy for Inoperable Case of Squamous Cell Carcinoma

IMpower130 Supports Atezolizumab Inclusion in Stage IV Lung Cancer Therapy

HannaH Trial: Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer

Pinpointing Best Dose of Immunotherapy (AMG 420) in Resistant Myeloma

VALENTINO Study: Comparing Maintenance Therapies in Metastatic Colorectal Cancer

Is Adding Entinostat to Avelumab of Benefit in Treating Advanced Epithelial Ovarian Cancer?

Does Stereotactic Body Radiotherapy Enhance the Effect of Immunotherapy for Lung Cancer?

Melanoma Brain Metastases: Can Nivolumab and Ipilimumab Cross the Blood-Brain Barrier?

CASSIOPEIA Trial: Daratumumab Combination Therapy for Newly Diagnosed Multiple Myeloma

First-Line Treatment With Atezolizumab Plus Bevacizumab Versus Sunitinib in Kidney Cancer

Use of Avelumab in Merkel Cell Carcinoma: Linking Early Response With Overall Survival

Tumor-Infiltrating Immune Cell Characteristics and Recurrence of Clear Cell Kidney Cancer

Meta-analysis of Treatment of Skin Cancers With PD-1/PD-L1 Inhibitors

Niraparib Plus Pembrolizumab in Triple-Negative Breast Cancer: TOPACIO/KEYNOTE-162 Trial

Adding Erlotinib to Bevacizumab in EGFR-Positive Lung Cancer

Immune-Related Adverse Events With Nivolumab: Predicting Outcomes in Kidney Cancer

Phase I Study Findings With bb2121 in Resistant Myeloma

Adding Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC

Long-Term Outcomes With Adjuvant Paclitaxel and Trastuzumab in HER2-Positive Breast Cancer

IV Versus IP Chemotherapy Plus Bevacizumab in Advanced Ovarian Cancer

Predicting Response to Immunotherapy for Kidney Cancer With FDG-PET/CT

Correlation Between Blood and Tumor T-Cell Cytotoxicity May Predict Treatment Effectiveness

Combination Therapy May Be Key to Treating KRAS-Mutant NSCLC

First-Line Combination Therapy in Metastatic Kidney Cancer: Answers and More Questions

Immunotherapy for Advanced Lung Cancer: Is Tumor Mutational Burden Linked to Response?

Does Squamous Cell Carcinoma Risk Change With Immunosuppression?

Can a Single Dose of PD-1 Inhibitor Before Surgery Predict Outcomes in Melanoma?

KEYNOTE-426 Trial: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer

Nivolumab/Ipilimumab in Advanced Melanoma: Comparison of Dosing Regimens

KAMILLA Trial: T-DM1 Safety in HER2-Positive Breast Cancer

Tisotumab Vedotin Exhibits Antitumor Activity in Bladder Cancer, Among Other Cancers

Treatment With Avelumab in Resistant Ovarian Cancer

Immunotherapy for Patients With NSCLC and HIV Infection

JAVELIN Renal 101 Trial: Axitinib Plus Avelumab in Kidney Cancer

New Combination Therapy for NSCLC Tested in Phase II Trial

Ovarian Carcinosarcoma: Update on a Rare Malignancy

Dasatinib in CML: Activating Natural Killer Cells

Use of Pembrolizumab in First-Line Treatment of Merkel Cell Carcinoma

Tisotumab Vedotin Exhibits Antitumor Activity in NSCLC, Among Other Cancers

Pembrolizumab Versus Platinum-Based Chemotherapy in Advanced NSCLC

Immunotherapy for Patients With Melanoma and HIV Infection

Patient-Reported Outcomes in Advanced Renal Cell Carcinoma

Tisotumab Vedotin Exhibits Antitumor Activity in Ovarian Cancer, Among Other Cancers

Use of Cetuximab in Multimodality Treatment of Cutaneous Squamous Cell Carcinoma

ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide/Dexamethasone in Resistant Myeloma

Study of Combination Immune Checkpoint Blockade in Stage III Melanoma Halted

Neoadjuvant Pembrolizumab Before Surgery in Muscle-Invasive Bladder Carcinoma

Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC

Combination Immunotherapy in First-Line Treatment of Advanced Kidney Cancer

Use of Pembrolizumab for Active Brain Metastases in Patients With Melanoma

Chemosensitivity Mediator and Immunotherapy Target Identified in Ovarian Cancer

Combination Epacadostat and Pembrolizumab in NSCLC

Clinical Benefits of Cetuximab Versus Cisplatin in HPV-Positive Oropharyngeal Cancer

Safety of Daratumumab in Relapsed or Refractory Multiple Myeloma

Combination of Epacadostat and Pembrolizumab in Advanced Melanoma

Durvalumab With or Without Tremelimumab in Subgroup of Resistant Head and Neck Cancer

Atezolizumab in Metastatic Triple-Negative Breast Cancer: Long-Term Outcomes

JAVELIN Lung 200: Avelumab Versus Docetaxel in Advanced Lung Cancer

Pembrolizumab-Associated Dermatomyositis in a Patient With Melanoma

ELOQUENT-2 Trial: Long-Term Benefits of Triplet Therapy in Multiple Myeloma

Alliance Study: Comparing Neoadjuvant Therapy Approaches in HER2-Positive Breast Cancer

Immunotherapy for Stage III Melanoma: Neoadjuvant vs. Adjuvant

Combining TKIs and Immune Checkpoint Inhibitors in Advanced Kidney Cancer

Do Brain Metastases Affect Outcomes With Immunotherapy?

Choosing Among First-Line Treatments in Advanced Kidney Cancer

MAVORIC Results Support FDA Approval of Mogamulizumab in Cutaneous C-Cell Lymphoma

Case Study Highlights Novel Concurrent Therapy for Cutaneous Squamous Cell Carcinoma

Does Following Induction Therapy With Cetuximab Radiotherapy Improve Outcomes in Head and Neck Cancers?

Does Baseline Steroid Use Impact Efficacy of Immunotherapy in Patients With NSCLC?

ASCO Clinical Practice Guidelines Updates in Advanced HER2-Positive Breast Cancer

Update on Nonsurgical Treatments of Non-Melanoma Skin Cancer

Bevacizumab Plus Immune Checkpoint Inhibition in Renal Cell Carcinoma

Neoadjuvant Chemotherapy Plus Panitumumab in Inflammatory Breast Cancer

Are Patients With Chronic Lymphocytic Leukemia at Risk for Melanoma?

ASCO Guideline Update: Adjuvant Chemotherapy and Targeted Therapy for Breast Cancer

Can Patients With Melanoma Benefit From Antigen-Specific Immunotherapeutic?

Review Features Clinical Challenges of Personalized Treatment in NSCLC

Comparing Trastuzumab Biosimilar and Reference Trastuzumab in HER2-Positive Breast Cancer

Immunotherapy in Multiple Myeloma: Today and Tomorrow

Is Ado-Trastuzumab Emtansine Active in HER2-Mutant Lung Cancer?

Closer Look at Therapeutic Interventional Clinical Trials in Multiple Myeloma

Delayed Skin Reactions Reported With PD-1 Inhibitors

Radiosurgery Plus Immunotherapy in Patients With Brain Metastases From Melanoma

Does Prior Antibiotic Use Affect Treatment Outcomes in Lung Cancer?

Combination Pazopanib Plus Cetuximab Therapy Warrants Further Study

Responses to Immune Checkpoint Inhibitors in Patients With NRAS-Mutant Melanoma

Novel Antibody-Drug Conjugate in Platinum-Resistant Ovarian Cancer

New Guidelines for Treating Metastatic Merkel Cell Carcinoma: Focus on Immunotherapy

Intensified Treatment Approach May Improve Survival in Some Patients With Myeloma

First-Line Avelumab for Metastatic Merkel Cell Carcinoma

Who Does Better on Anti–PD-1 Therapy for Melanoma: Younger or Older Patients?

Is Elotuzumab Monotherapy Beneficial in Patients With Smoldering Multiple Myeloma?

Novel Immunotherapy for Poor-Prognosis Relapsed Multiple Myeloma

Study Sheds Light on Dendritic Cell Subsets in Tonsillar Cancer

Baseline Tumor Size and Prognosis in Pembrolizumab-Treated Melanoma

Immune Stimulant in Combination With Nivolumab for Metastatic Lung Cancer

Efficacy of Immunotherapy for Melanoma: Does Gender Matter?

Noninterventional Study of Lenalidomide Plus Dexamethasone in Resistant Myeloma

Treating Nasopharyngeal Carcinoma With Nivolumab

Efficacy of Immunotherapy for Lung Cancer: Does Gender Matter?

Addition of CAR T-Cell Therapy to Stem Cell Transplantation in Refractory Multiple Myeloma

Health-Related Quality of Life With Pembrolizumab for Advanced Urothelial Cancer

Pilot Clinical Trial of Dendritic Cell Vaccination in Ovarian Cancer

Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types

Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types

Updated ASCO Guideline for Use of Bone-Modifying Agents in Multiple Myeloma

Comparison of Nivolumab/Ipilimumab and Sunitinib in Advanced Kidney Cancer

DDR Genes and Response to Checkpoint Blockade in Urothelial Cancer

Durvalumab in Heavily Pretreated Patients With Advanced Lung Cancer

PD-1 Blockade in Advanced Desmoplastic Melanoma

Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types

Long-Term Survival With Nivolumab in Pretreated Patients With Advanced Lung Cancer

Outcomes When Patients With Melanoma Discontinue Nivolumab/Ipilimumab Combination

Genomic Alterations in Clear Cell Renal Cell Carcinoma and Response to Immune Checkpoint Inhibitors

Denosumab Versus Zoledronic Acid for Treating Myeloma With Bone Disease

Continuation of Immunotherapy Beyond Disease Progression in Advanced Melanoma

Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma

Are Two Monoclonal Antibodies Better Than One in Advanced Melanoma?

Long-Term Survival With Pembrolizumab for Advanced Melanoma

Nivolumab Versus Ipilimumab in Patients With Resected Advanced Melanoma

Does Small Cell Ovarian Cancer Respond to Immunotherapy?

ASPIRE Trial: Triplet Therapy in Relapsed or Refractory Multiple Myeloma

Gene Discovery May Shed Light on Mechanism of Immunotherapy Resistance

Long-Term Outcomes With Atezolizumab in Metastatic Urothelial Carcinoma

Considering Newer Agents in Managing Relapse in Resistant Myeloma

Axitinib Plus Pembrolizumab in Advanced Kidney Cancer

BCMA as a Therapeutic Target and Biomarker in Multiple Myeloma

Dual HER2 Blockade in Metastatic Breast Cancer

Clinical Practice Update on Bone-Modifying Agents in Patients With Multiple Myeloma

Pertuzumab-Containing Neoadjuvant Regimens in HER2-Positive Breast Cancer

Dual HER2-Targeting Treatments for Postmenopausal Women With Metastatic Breast Cancer

Combination Therapy for Previously Untreated Advanced Lung Cancer

Early Research Studies May Advance the Treatment of Multiple Myeloma

Avelumab as Second-Line Treatment for Advanced Urothelial Carcinoma

Effect of Pembrolizumab on Quality of Life for Patients With Advanced Lung Cancer

Novel Antibody Clone for Targeting Multiple Myeloma Cancer Cells

Should Bevacizumab Accompany Adjuvant Chemotherapy in Early-Stage NSCLC?

Long-Term Outcomes With Nivolumab vs. Docetaxel in Advanced Lung Cancer

Safety of Checkpoint Inhibitors Plus Radiotherapy for Metastatic Lung Cancer

Cardiac Effects of Trastuzumab Therapy in Patients With HER2-Positive Breast Cancer

Cost-Effectiveness Comparisons of Treatments for Heavily Pretreated Multiple Myeloma

Can Type of Myeloma Influence Response to Monoclonal Antibodies?

Hair Repigmentation and Response to Immunotherapy for NSCLC

Gene Signature in Predicting Response to Immunomodulatory Derivatives in Myeloma

Are Immune-Related Adverse Events With Nivolumab Linked to Efficacy in NSCLC?

Neoadjuvant Combination Therapy for HER2-Positive Primary Breast Cancer

HER2-Targeted Therapy and Breast Reconstruction

Immunotherapy After Chemoradiotherapy for Stage III Lung Cancer

Post-Progression Response to Nivolumab in Advanced Renal Cell Carcinoma

Adding First-Line Ipilimumab to Chemotherapy for Squamous NSCLC

Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma

Neoadjuvant Ado-trastuzumab Emtansine vs. Trastuzumab in Early Breast Cancer

Lenalidomide Maintenance After Transplantation in Multiple Myeloma

Bevacizumab Plus Novel Monoclonal Antibody in Metastatic Kidney Cancer

Response to Immunotherapy in Patients With ‘Claudin-Low’ Breast Tumors

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Comparing Trastuzumab-Based Regimens in Older Women With Early-Stage Breast Cancer

Thyroid Dysfunction in Patients Receiving Immunotherapy for Advanced Kidney Cancer

Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer

Pembrolizumab as Second-Line Treatment for Advanced Urothelial Carcinoma

Adding Pertuzumab to Trastuzumab and Chemotherapy in HER2-Positive Breast Cancer

Atezolizumab in PD-L1–Selected Advanced Non–Small Cell Lung Cancer

Cost Analysis of Personalized vs Fixed Dosing of Pembrolizumab

Final Survival Data From TH3RESA Trial in Breast Cancer

Final Overall Survival Data From EMILIA Trial

Early-Phase Trial of Vaccine in NSCLC

Combining Monoclonal Antibodies in HER2-Positive Breast Cancer

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Atezolizumab vs Docetaxel in Patients With Previously Treated NSCLC (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial